Materials and methods for improved intragastric balloon devices

Information

  • Patent Grant
  • 9149611
  • Patent Number
    9,149,611
  • Date Filed
    Tuesday, February 8, 2011
    13 years ago
  • Date Issued
    Tuesday, October 6, 2015
    8 years ago
Abstract
Disclosed is a balloon of an intragastric device, comprising, in combination: a core of a first material and having an inner surface and an outer surface; and a coating of a second material on at least one of the inner surface of the core and the outer surface of the core. Disclosed is a method, comprising, in combination: creating a core of a balloon by a core in a first material; dipping at least one of an inner surface of the core and an outer surface of the core in a second material, whereby a coating is formed on at least one of the inner surface of the core and the outer surface of the core. The first material may be of a more dimensional consistency than the second material, have a greater elasticity than the second material, or be primarily of polydimethyl-siloxane.
Description
BACKGROUND

This disclosure relates to implantable, expandable gastric devices. In particular, this disclosure relates to improved structures of balloons and methods of producing the same.


Many conventional implantable gastric devices have a balloon filled with a biocompatible fluid. Such gastric devices are generally inserted into the stomach when the balloon is deflated and then inflated in vivo. The gastric devices are often left in the stomach for an extended period of time to treat severe obesity or other conditions. The gastric devices are eventually removed after completing the treatment or for other reasons by deflating the balloon, grasping the gastric device with an extraction tool, and extracting the gastric device via the esophagus and mouth. Conventional gastric devices are deflated by attempting to puncture the balloon and aspirate the biocompatible fluid through a needle.


One challenge of conventional devices is that the balloon are generally fairly large in a deflated state because of the limited elasticity and expansion of the materials that can withstand the harsh environment within the stomach rupture. Many existing balloons for intragastric devices are made from polydiphenylsiloxane (PDPS), which resists degradation by acids, fungal growth and other microbial growth, but it has limited expansion. As such, the cuffs of such a balloon must have a fairly large diameter so that the balloon can be removed from a mandrel during the manufacturing process.


Another challenge of conventional intragastric devices is the life span of the balloon. For example, fungi or other microbes can grow into the material of the balloon and effectively decrease the wall thickness. This can weaken the balloon wall to the point that it ruptures under the pressure of the fluid in the balloon.





BRIEF DESCRIPTION OF THE DRAWINGS

Several embodiments of the present technology will become more apparent with reference to the following description taken in conjunction with the accompanying drawings wherein like reference numerals denote like elements and in which:



FIG. 1 shows a perspective view of a balloon;



FIG. 2 shows a perspective view of an intragastric device;



FIG. 3 shows a side view of an intragastric device;



FIG. 4 shows a top view of an intragastric device;



FIG. 5 shows a sectional view of a balloon with a magnified view;



FIG. 6 shows a sectional view of a balloon with a magnified view; and



FIG. 7 shows a sectional view of a balloon with a magnified view.





DETAILED DESCRIPTION

Specific details of several embodiments of the present technology are described below with reference to an intragastric device with compound balloon. Although many of the embodiments are described below with respect to a dual balloon intragastric device, other types of devices with only one balloon or more than two balloons may be within the scope of the technology. Moreover, several other embodiments of the technology can have different configurations, components, or procedures than those described in this section. A person of ordinary skill in the art, therefore, will accordingly understand that the technology may have other embodiments with additional elements, or the technology may have other embodiments without several of the features shown and described below with reference to FIGS. 1-7.


Several embodiments of the technology are directed to a balloon of an intragastric device comprising, in combination, a substrate or core of a first material that has having an inner surface and an outer surface, and a coating of a second material on at least one of the inner or outer surfaces. The substrate, for example, can be more elastic and/or have more expansion than the coating, and the coating can be more resistant to fungal or other microbial growth than the substrate.


Additional embodiments of the technology are directed to a method comprising, in combination, forming a core or substrate of a first material into a balloon and covering at least one of an inner surface and/or outer surface of the substrate with a second material. The second material can be a coating that is sprayed, painted or applied by dipping the substrate into the second material, to form a smoother surface finish, as compared to a surface finish of a molded core, having a roughness from about 0.1 to 0.7 micron. This further inhibits or otherwise impedes the formation of biofilm (e.g., candida) on the coated surface of the balloon. Also disclosed are products by processed disclosed herein.


The first material may be of a more dimensionally stable or consistant than the second material and/or have a greater elasticity than the second material. In one embodiment, the first material comprises polydimethylsiloxane (PDMS). The second material may have a higher resistance to acid, be more resistant to fungal or other microbial activity, and be less permeable than the first material. In one embodiment, the second material comprises PDPS.


In the specific embodiment shown in FIG. 1, a balloon 30 can be one of several expandable, space filling components. In several embodiments, and as shown in FIG. 2, the balloon 30 may be a component of an intragastric device 10. For example, as further shown in FIG. 2, the intragastric device 10 can have a shaft 20 and a plurality of the balloons 30 may be joined or otherwise carried by the shaft 20.


The balloon 30 may have many different geometries and shapes according to the specific anatomy in which the balloon 30 is implanted. As shown in FIGS. 1 and 3, the balloon 30 may have at least one cuff 40 for interfacing with the shaft 20 (FIG. 2) such that the shaft 20 extends through the balloon 30. The balloon 30 may be an open or closed balloon, and the balloon 30 may have an inner surface and outer surface.


According to several embodiments of the technology, the intragastric device 10 may be configured for use as an implantable device within a gastric cavity. In many applications, the intragastric device 10 is implanted for several months in the stomach or other gastric cavity having high concentrations of acids and microbes that can deteriorate the balloon 30. The durability and longevity of the intragastric device 10 is accordingly defined, at least in part, by the ability of the balloon 30 to resist the harsh environment within the stomach. As such, the materials and manufacturing methods of the materials are key contributors as to balloon integrity and longevity.


According to embodiments, the balloon 30 may comprise a combination of two different silicone-containing materials. Two examples of such materials are PDMS and PDPS. PDMS may be represented as [SiO(CH3)2]n or graphically as follows:




embedded image


PDPS may be represented as [SiO(C6H5)2]n or graphically as follows:




embedded image


According to several embodiments of the technology, at least one of PDMS and PDPS may form the substrate or core of at least a portion of the balloon 30. Other materials, structures, or compounds may be mixed or cross-linked with the based material.


According to several embodiments of the technology, a plasma etching or coating may be provided to at least a portion of the balloon 30. Plasma etching may involve a high-speed stream of glow discharge (plasma) of an appropriate gas mixture being shot (in pulses) at a sample. The plasma source can be either charged (ions) or neutral (atoms and radicals). During the process, the plasma will generate volatile etch products at room temperature from the chemical reactions between the elements of the material etched and the reactive species generated by the plasma. The atoms of the shot element embed themselves at or just below the surface of the target, thus modifying the physical properties of the balloon 30. Etching may facilitate better adherence between layers of the balloon 30.


According to several embodiments of the technology, various coatings (e.g., hydrophilic) may be applied to at least a portion of substrate or core of the balloon 30. For example, a hydrophilic coating may be provided where two surfaces of the balloon 30 resist flow of fluid there through.


The respective chemical structures of PDMS and PDPS have relatively disparate characteristics, which may be summarized as follows:
















Polydimethylsiloxane
Polydiphenylsiloxane


















Manufacturing
Molding, extrusion
Dipping


method:


Curing:
Heat
Heat


Consistency:
More dimensional (moldable)
Less dimensional




(dipping)


Elasticity:
Higher
Lower


Tensile Strength:
Lower
Higher


Acid resistance:
Acceptable
Increased


Permeability:
Higher
Lower










In various applications and based on different aspects, each of PDMS and PDPS may be seen as providing certain advantages and disadvantages.


According to several embodiments of the technology, the dimensional stability or consistency and elasticity of PDMS materials and PDMS blends enable the balloon 30 to be formed using molding and extrusion processes instead of a dipping process. In particular, molding processes include molding the PDMS material over a mandrel, and the higher elasticities of PDMS materials compared to PDPS materials reduce the stresses involved in removing the mandrel. For example, the balloon 30 may be formed using a mandrel that has a larger diameter at a central portion than at one or both ends (corresponding to cuffs 40). For example, the diameter at the middle of a mandrel may be up to 600% larger than at the end of the mandrel. The balloon 30 must sufficiently elastic to remove the mandrel through the cuff 40 without damaging the cuff 40.


According to several embodiments of the technology, the expansion ratio of the balloon 30 from an uninflated state (i.e., before and during implant) to an inflated state (i.e, after implant) may be significant. For example, the balloon 30 may have an outer diameter of about 1.9″ in an uninflated state and about 4″ in an inflated state (over 200% expansion). By further example, the balloon 30 may have a volume of about 80 cc in an uninflated state and about 450 cc in an inflated state (over 500% expansion). These factors are well-served by PDMS materials and PDMS blends. As such, PDMS and PDMS blends are well suited for the substrate or core of the balloon 30.


In accordance with several embodiments of the invention, the higher acid resistance and less permeability of PDPS materials and PDPS blends, compared to PDMS based materials, better limit the ingress or egress of materials across the walls of the balloon 30 and support longevity of the balloon 30. Generally, PDPS, as compared to PDMS, is less able to provide consistent wall thicknesses and is less capable of generating molding friendly features, but more capable of resisting acids and growth of fungi or bacteria.


In several specific embodiments of the technology, the balloon 30 has a multiple-material composition in which a plurality of disparate materials and material blends may be provide in layers forming walls of the balloon 30. For example, a wall of the balloon 30 may have a substrate or core with at least one coating on an inner or outer surface thereof.



FIGS. 5 and 6 illustrate specific embodiments of the technology. In the embodiment shown in FIG. 5, the balloon can have a substrate or core 50 and outer coating 60a over an outer surface of the core 50. The outer coating 60a may be provided, for example, by a dipping process after core 50 is formed. In the embodiment shown in FIG. 6, the balloon 30 can have in inner coating 60b over an inner surface of the core 50. The inner coating 60b may be provided, for example, by a dipping process after core 50 is formed and the balloon inverted inside-out.



FIG. 7 illustrates another embodiment in which the balloon has the substrate or core 50, the outer coating 60a over the outer surface of the core, and an inner coating 60b over the inner surface of the core 50. The outer coating 60a and inner coating 60b may be provided, for example, by a dipping process after core 50 is formed.


In selected embodiments, the substrate or core 50 can comprise PDMS or another material that is moldable and has a higher elasticity than PDPS. The inner and/or outer coatings 60a-b can comprises PDPS or another material that is less permeable and more acid resistant than PDMS. According to several embodiments, the balloon 30 having a layered, multiple-material composition may benefit from the advantaged of each material while mitigating or minimizing the detriments of each.


The present technology is also directed to methods of making the balloon 30 is disclosed. In one embodiment, the substrate or core 50 may be molded of the first material, such as a liquid silicone rubber (LSR) grade material (e.g., such as PDMS). Those skilled in the art will recognize various molding and extrusion processes that may facilitate formation of core 50. The molding process can include injecting PDMS or a PDMS blend into a mold such that the molded material surrounds a mandrel or other form. After curing, the core 50 is removed from the mold, mandrel, or other device, and then the second material may be coated onto the inner and/or outer surface of the core 50. For example, the core 50 may be dipped in the second material to form at least one of the outer coating 60a and/or the inner coating 60b. Other embodiments of the method, the core 50 may be coated using other techniques, such as spraying, painting, coating, washing, etc. The second material can be PDPS or another suitable low-permeable, acid and fungal resistant material.


The core 50 may compose a substantial portion of the total sum of the balloon 30 or at least the walls thereof. For example, the thickness of core 50 may be about 0.001 inch to about 1.0 inch. By further example, the thickness of core 50 may be about 0.024 inch to about 0.030 inch. The core 50 can have other thicknesses based on the needs and applications of the desired product.


The outer coating 60a or the inner coating 60b may be a thin relative to the thickness of core 50. For example, the outer coating 60a or the inner coating 60b may have a thickness of about 1% to about 99% of the thickness of core 50. By further example, the outer coating 60a or the inner coating 60b may have a thickness of about 10% to about 20% of the thickness of core 50. The inner and outer coating 60a-b can have other thicknesses based on the needs and applications of the desired product. It should be noted that outer coating 60a or inner coating 60b comprising PDPS materials increase the stiffness of the balloon 30 and reduce elongation properties thereof.


In still additional embodiments of the technology, the core 50 and/or the coating 60 can include anti-microbial or other additives to impart additional therapeutic, durability, or other properties to the balloon 30. For example, such additives can be distributed homogeneously in the coating 60, or the additives can be a constituent of another coating applied directly to the core 50 or to the coating 60. When such an additional coating is applied directly to the core 50, the coating 60 can be applied onto the other coating. In several specific examples, the additives can comprise salt or silver-based anti-microbial materials that inhibit the growth of microbes on and/or into the core 50.


The multi-layered construction of first and second materials of several embodiments of the balloon may have a substantially consistent surface and retain elastic material properties, increased acid resistance, and lower permeability. For example, the first material of the core 50 can provide good elasticity enable molding processes that provide a controlled wall thickness, and the second material of the coating 60 can provide good resistance to acid, fungus, bacteria and other microbes. The second material of the coating 60 can also have a low permeability.


Although the method and agent have been described in terms of what are presently considered to be the most practical and preferred embodiments, it is to be understood that the disclosure need not be limited to the disclosed embodiments. It is intended to cover various modifications and similar arrangements included within the spirit and scope of the claims, the scope of which should be accorded the broadest interpretation so as to encompass all such modifications and similar structures. The present disclosure includes any and all embodiments of the following claims.


It should also be understood that a variety of changes may be made without departing from the essence of the invention. Such changes are also implicitly included in the description. They still fall within the scope of this invention. It should be understood that this disclosure is intended to yield a patent covering numerous aspects of the invention both independently and as an overall system and in both method and apparatus modes.


Further, each of the various elements of the invention and claims may also be achieved in a variety of manners. This disclosure should be understood to encompass each such variation, be it a variation of an embodiment of any apparatus embodiment, a method or process embodiment, or even merely a variation of any element of these.


Particularly, it should be understood that as the disclosure relates to elements of the invention, the words for each element may be expressed by equivalent apparatus terms or method terms—even if only the function or result is the same.


Such equivalent, broader, or even more generic terms should be considered to be encompassed in the description of each element or action. Such terms can be substituted where desired to make explicit the implicitly broad coverage to which this invention is entitled.


It should be understood that all actions may be expressed as a means for taking that action or as an element which causes that action.


Similarly, each physical element disclosed should be understood to encompass a disclosure of the action which that physical element facilitates.


Any patents, publications, or other references mentioned in this application for patent are hereby incorporated by reference. In addition, as to each term used it should be understood that unless its utilization in this application is inconsistent with such interpretation, common dictionary definitions should be understood as incorporated for each term and all definitions, alternative terms, and synonyms such as contained in at least one of a standard technical dictionary recognized by artisans and the Random House Webster's Unabridged Dictionary, latest edition are hereby incorporated by reference.


Finally, all referenced listed in the Information Disclosure Statement or other information statement filed with the application are hereby appended and hereby incorporated by reference; however, as to each of the above, to the extent that such information or statements incorporated by reference might be considered inconsistent with the patenting of this/these invention(s), such statements are expressly not to be considered as made by the applicant(s).


In this regard it should be understood that for practical reasons and so as to avoid adding potentially hundreds of claims, the applicant has presented claims with initial dependencies only.


Support should be understood to exist to the degree required under new matter laws—including but not limited to United States Patent Law 35 USC 132 or other such laws—to permit the addition of any of the various dependencies or other elements presented under one independent claim or concept as dependencies or elements under any other independent claim or concept.


To the extent that insubstantial substitutes are made, to the extent that the applicant did not in fact draft any claim so as to literally encompass any particular embodiment, and to the extent otherwise applicable, the applicant should not be understood to have in any way intended to or actually relinquished such coverage as the applicant simply may not have been able to anticipate all eventualities; one skilled in the art, should not be reasonably expected to have drafted a claim that would have literally encompassed such alternative embodiments.


Further, the use of the transitional phrase “comprising” is used to maintain the “open-end” claims herein, according to traditional claim interpretation. Thus, unless the context requires otherwise, it should be understood that the term “compromise” or variations such as “comprises” or “comprising”, are intended to imply the inclusion of a stated element or step or group of elements or steps but not the exclusion of any other element or step or group of elements or steps.


Such terms should be interpreted in their most expansive forms so as to afford the applicant the broadest coverage legally permissible.

Claims
  • 1. An intragastric balloon, comprising, in combination: a core of a first material and having an inner surface and an outer surface; anda coating of a second material on at least one of the inner surface of the core and the outer surface of the core, wherein the first material is more elastic than the second material and the second material has a lower permeability than the first material, and wherein the second material comprises polydiphenylsiloxane.
  • 2. The intragastric balloon of claim 1, further comprising two cuffs configured to receive a shaft extended through the intragastric balloon.
  • 3. The intragastric balloon of claim 1, wherein the first material is of a more dimensional consistency than the second material.
  • 4. The intragastric balloon of claim 1, wherein the first material has a viscosity suitable for molding processes.
  • 5. The intragastric balloon of claim 1, wherein the first material is primarily of polydimethylsiloxane.
  • 6. The intragastric balloon of claim 5, wherein the second material has higher acid resistance than the first material.
  • 7. The intragastric balloon of claim 1, wherein the second material is less permeable than the first material.
  • 8. The intragastric balloon of claim 1, wherein the intragastric balloon has an expansion ratio of at least about 200% by diameter and at least about 500% by volume.
  • 9. An intragastric device, comprising, in combination: a shaft; andat least a first balloon fixed to the shaft, the first balloon having a core of a first material and a coating of a second material, the second material comprising polydiphenylsiloxane, wherein the core has an inner surface and an outer surface, and the coating is on at least one of the inner surface of the core and the outer surface of the core, and wherein the first material comprises polydimethylsiloxane.
CROSS-REFERENCE TO RELATED APPLICATION

The present application claims priority under 35 U.S.C. 371 of International Application Ser. No. PCT/US2011/024082, filed Feb. 8, 2011, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/302,465, filed Feb. 8, 2010, the entire contents of which is incorporated herein by reference in their entireties. This application incorporates by reference: U.S. Pat. Pub. No. 2007/0100367, published May 3, 2007; U.S. Pat. Pub. No. 2007/0100368, published May 3, 2007; U.S. Pat. Pub. No. 2007/0100369, published May 3, 2007; U.S. Pat. Pub. No. 2007/0149994, published Jun. 28, 2007; U.S. Pat. Pub. No. 2008/0243071, published Oct. 2, 2008; U.S. Pat. Pub. No. 2008/0319471, published Dec. 25, 2008; U.S. Pat. Pub. No. 2005/0159769, published Jul. 21, 2005; U.S. Pat. Pub. No. 2009/0048624, published Feb. 19, 2009; WIPO Pub. No. WO 2007/053556, published Oct. 5, 2007; WIPO Pub. No. WO 2007/053707, published Oct. 5, 2007; WIPO Pub. No. WO 2007/053706, published Oct. 5, 2007; and WIPO Pub. No. WO 2007/075810, published May 7, 2007; each as if fully set forth herein in its entirety.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2011/024082 2/8/2011 WO 00 8/28/2012
Publishing Document Publishing Date Country Kind
WO2011/097637 8/11/2011 WO A
US Referenced Citations (157)
Number Name Date Kind
2493326 Trinder Jan 1950 A
4133315 Berman et al. Jan 1979 A
4198983 Becker et al. Apr 1980 A
4246893 Berson Jan 1981 A
4356824 Vazquez Nov 1982 A
4416267 Garren et al. Nov 1983 A
4465072 Taheri Aug 1984 A
4465818 Shirahata et al. Aug 1984 A
4485805 Foster, Jr. et al. Dec 1984 A
4543089 Moss Sep 1985 A
4598699 Garren et al. Jul 1986 A
4694827 Weiner et al. Sep 1987 A
4723547 Kullas et al. Feb 1988 A
4899747 Garren et al. Feb 1990 A
4940458 Cohn Jul 1990 A
5073347 Garren et al. Dec 1991 A
5084061 Gau et al. Jan 1992 A
5123840 Nates Jun 1992 A
5234454 Bangs Aug 1993 A
5259399 Brown Nov 1993 A
5263934 Haak Nov 1993 A
5273536 Savas Dec 1993 A
5318530 Nelson Jun 1994 A
5334187 Fischell et al. Aug 1994 A
5431173 Chin et al. Jul 1995 A
5496271 Burton et al. Mar 1996 A
5516812 Chu et al. May 1996 A
5575772 Lennox Nov 1996 A
5639810 Smith et al. Jun 1997 A
5643209 Fugoso et al. Jul 1997 A
5730722 Wilk Mar 1998 A
5779728 Lunsford et al. Jul 1998 A
5857991 Grothoff et al. Jan 1999 A
5876376 Schwab et al. Mar 1999 A
5938669 Klaiber et al. Aug 1999 A
5993473 Chan Nov 1999 A
5997503 Willis et al. Dec 1999 A
6149621 Makihara Nov 2000 A
6254355 Gharib Jul 2001 B1
6276567 Diaz et al. Aug 2001 B1
6280411 Lennox Aug 2001 B1
6423058 Edwards et al. Jul 2002 B1
6427089 Knowlton Jul 2002 B1
6454785 De Hoyos Garza Sep 2002 B2
6524234 Ouchi Feb 2003 B2
6535764 Imran et al. Mar 2003 B2
6540789 Silverman Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6579301 Bales et al. Jun 2003 B1
6592552 Schmidt Jul 2003 B1
6613018 Bagga et al. Sep 2003 B2
6613037 Khosravi et al. Sep 2003 B2
6706010 Miki et al. Mar 2004 B1
6746460 Gannoe et al. Jun 2004 B2
6826428 Chen et al. Nov 2004 B1
6850128 Park Feb 2005 B2
6866657 Shchervinsky et al. Mar 2005 B2
6869431 Maguire et al. Mar 2005 B2
6890300 Lloyd et al. May 2005 B2
6890346 Ganz et al. May 2005 B2
6902535 Eberhart et al. Jun 2005 B2
6923754 Lubock Aug 2005 B2
6931286 Sigg et al. Aug 2005 B2
6939299 Petersen et al. Sep 2005 B1
6958052 Charlton Oct 2005 B1
7001419 DiCaprio et al. Feb 2006 B2
7016735 Imran et al. Mar 2006 B2
7020531 Colliou et al. Mar 2006 B1
7033373 De la Torre et al. Apr 2006 B2
7056305 Garza Alvarez Jun 2006 B2
7076305 Imran et al. Jul 2006 B2
7081125 Edwards et al. Jul 2006 B2
7131945 Fink et al. Nov 2006 B2
7483746 Lee et al. Jan 2009 B2
7625355 Yu Dec 2009 B2
7828749 Douglas et al. Nov 2010 B2
8083757 Gannoe et al. Dec 2011 B2
20010022988 Schwarz et al. Sep 2001 A1
20010037127 De Hoyos Garza Nov 2001 A1
20020055757 Torre May 2002 A1
20020107515 Edwards et al. Aug 2002 A1
20020161388 Samuels et al. Oct 2002 A1
20020173804 Rousseau Nov 2002 A1
20030114878 Diederich et al. Jun 2003 A1
20030171768 McGhan Sep 2003 A1
20030187390 Bates et al. Oct 2003 A1
20040044354 Gannoe et al. Mar 2004 A1
20040059289 Garza Alvarez Mar 2004 A1
20040059290 Palasis Mar 2004 A1
20040073162 Bleam et al. Apr 2004 A1
20040087902 Richter May 2004 A1
20040106899 McMichael et al. Jun 2004 A1
20040116897 Aboul-Hosn Jun 2004 A1
20040127915 Fleenor et al. Jul 2004 A1
20040186502 Sampson et al. Sep 2004 A1
20040220665 Hossainy et al. Nov 2004 A1
20040236280 Rice et al. Nov 2004 A1
20040236361 Sakurai Nov 2004 A1
20040254600 Zarbatany et al. Dec 2004 A1
20050027283 Richard et al. Feb 2005 A1
20050027313 Shaker Feb 2005 A1
20050038415 Rohr et al. Feb 2005 A1
20050055039 Burnett et al. Mar 2005 A1
20050059990 Ayala Mar 2005 A1
20050075624 Miesel Apr 2005 A1
20050085792 Gershowitz Apr 2005 A1
20050119674 Gingras et al. Jun 2005 A1
20050131442 Yachia et al. Jun 2005 A1
20050143784 Imran Jun 2005 A1
20050159769 Alverdy Jul 2005 A1
20050177103 Hunter et al. Aug 2005 A1
20050192614 Binmoeller Sep 2005 A1
20050192615 Torre et al. Sep 2005 A1
20050267595 Chen et al. Dec 2005 A1
20050267596 Chen et al. Dec 2005 A1
20050273060 Levy et al. Dec 2005 A1
20060058829 Sampson et al. Mar 2006 A1
20060178691 Binmoeller Aug 2006 A1
20060184112 Horn et al. Aug 2006 A1
20060259020 Sharratt Nov 2006 A1
20070016262 Gross et al. Jan 2007 A1
20070078476 Hull et al. Apr 2007 A1
20070093728 Douglas et al. Apr 2007 A1
20070100367 Quijano May 2007 A1
20070100368 Quijano May 2007 A1
20070100369 Cragg May 2007 A1
20070135829 Paganon Jun 2007 A1
20070142770 Rioux et al. Jun 2007 A1
20070149994 Sosnowski Jun 2007 A1
20070173881 Birk et al. Jul 2007 A1
20070233161 Weller et al. Oct 2007 A1
20070250020 Kim et al. Oct 2007 A1
20070265369 Muratoglu et al. Nov 2007 A1
20070265598 Karasik Nov 2007 A1
20070288033 Murature et al. Dec 2007 A1
20080058887 Griffin et al. Mar 2008 A1
20080082056 Mauch et al. Apr 2008 A1
20080097513 Kaji et al. Apr 2008 A1
20080119729 Copa et al. May 2008 A1
20080172079 Birk Jul 2008 A1
20080190363 Chen et al. Aug 2008 A1
20080208135 Annunziata Aug 2008 A1
20080208241 Weiner et al. Aug 2008 A1
20080233167 Li et al. Sep 2008 A1
20080243071 Quijano Oct 2008 A1
20080243166 Paganon et al. Oct 2008 A1
20080255601 Birk Oct 2008 A1
20080319471 Sosnowski et al. Dec 2008 A1
20090048624 Alverdy Feb 2009 A1
20090259236 Burnett et al. Oct 2009 A2
20090275973 Chen et al. Nov 2009 A1
20100023047 Simpson Jan 2010 A1
20100130998 Alverdy May 2010 A1
20100243135 Pepper et al. Sep 2010 A1
20110178544 Sosnowski et al. Jul 2011 A1
20120271336 Hamman et al. Oct 2012 A1
20120289992 Quijano et al. Nov 2012 A1
Foreign Referenced Citations (42)
Number Date Country
8708978 Nov 1987 DE
0105481 Mar 1984 EP
0457456 May 1990 EP
0485903 Aug 1991 EP
1781183 May 2007 EP
2862525 May 2005 FR
2892297 Apr 2007 FR
2090747 Jul 1982 GB
2139902 Nov 1984 GB
S57168674 Oct 1982 JP
S6415063 Jan 1989 JP
H091872 Apr 1989 JP
H08322943 Dec 1996 JP
2001128985 May 2001 JP
2006333888 Dec 2006 JP
WO9000369 Jan 1990 WO
WO9925418 May 1999 WO
WO-0141700 Jun 2001 WO
WO-0166166 Sep 2001 WO
WO-0240081 May 2002 WO
WO2006035446 Apr 2006 WO
WO2006056944 Jun 2006 WO
WO2006128978 Dec 2006 WO
WO-2007027812 Mar 2007 WO
WO-2007053556 May 2007 WO
WO-2007053706 May 2007 WO
WO-2007053707 May 2007 WO
WO-2007075810 Jul 2007 WO
WO-2008042819 Apr 2008 WO
WO2008121831 Oct 2008 WO
WO-2009055386 Apr 2009 WO
WO2009112786 Sep 2009 WO
WO-2010048021 Apr 2010 WO
WO2010115161 Oct 2010 WO
WO2011011629 Jan 2011 WO
WO2011011741 Jan 2011 WO
WO2011011743 Jan 2011 WO
WO2011038270 Mar 2011 WO
WO2011024077 Aug 2011 WO
WO2011097637 Aug 2011 WO
WO2011127205 Oct 2011 WO
WO2012048226 Apr 2012 WO
Non-Patent Literature Citations (56)
Entry
European Supplementary Search Report; EP Application No. 10802994.3, Applicant: ReShape Medical, Inc., mailed Jun. 28, 2013, 8 pgs.
European Supplementary Search Report; EP Application No. 10802918.2, Applicant: ReShape Medical, Inc., mailed Jun. 5, 2013, 6 pgs.
Extended European Search Report; Application No. EP6827098.3, Applicant: Reshape Medical, Corporation, mailed on Aug. 25, 2014, 3 pages.
Extended European Search Report; Application No. EP6827314.3, Applicant: ReShape Medical Corporation mailed Aug. 1, 2014, 3 pages.
Extended European Search Report; Application No. EP6827313.5, Applicant: ReShape Medical Corporation, mailed Jul. 30, 2014, 5 pages.
Extended European Search Report; Application No. EP6847847.8, Applicant ReShape Medical Corporation, mailed Aug. 14, 2014, 5 pages.
Final Office Action; U.S. Appl. No. 13/858,767, mailed on May 30, 2014, 12 pages.
Non-Final Office Action; U.S. Appl. No. 13/386,638, mailed on Jun. 27, 2014, 12 pages.
Extended European Search Report; Application No. EP11766679.2, Applicant: Reshape Medical, Inc., mailed Dec. 12, 2013, 6 pages.
Extended European Search Report; Application No. EP11748141.6, Applicant: Reshape Medical, Inc., mailed Feb. 25, 2014, 6 pages.
European Search Report—Supplementary; EP 03726447.0, Applicant: Applied Medical Resources Corporation: Mar. 1, 2006, 3 pgs.
Final Office Action; U.S. Appl. No. 11/694,536, Mailing Date Mar. 11, 2011, 13 pages.
Final Office Action; U.S. Appl. No. 11/768,152, Mailing Date Jan. 19, 2011, 13 pages.
International Search Report; International Application No. PCT/US2010/042948; Applicant: ReShape Medical, Inc., Mailing Date Apr. 1, 2011, 11 pages.
International Search Report; International Application No. PCT/US2010/043134; Applicant: ReShape Medical, Inc., Mailing Date Apr. 27, 2011, 12 pages.
International Search Report; International Application No. PCT/US2010/043136; Applicant: ReShape Medical, Inc., Mailing Date Apr. 12, 2011, 9 pages.
International Search Report; International Application No. PCT/US2010/050260; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 17, 2011, 9 pages.
International Search Report; International Application No. PCT/US2011/026233; Applicant: ReShape Medical, Inc., Mailing Date Apr. 26, 2011, 9 pages.
International Search Report; International Application No. PCT/US2011/031463; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 27, 2011, 10 pages.
International Search Report; International Application No. PCT/US2003/012782, Applicant: Applied Medical Resources Corporation, dated: Oct. 28, 2003, 7 pages.
International Search Report; International Application No. PCT/US2006/042336, Applicant: Abdominus, Inc., dated: Mar. 14, 2007, 9 pages.
International Search Report; International Application No. PCT/US2006/042710, Applicant: Abdominus, Inc. et al., dated: Mar. 15, 2007, 9 pages.
International Search Report; International Application No. PCT/US2006/042711, Applicant: Abdominus, Inc. et al, dated: Mar. 16, 2007, 9 pages.
International Search Report; International Application No. PCT/US2006/048647, Applicant: Abdominus, Inc. et al., dated: May 22, 2007, 12 pages.
International Search Report; International Application No. PCT/US2008/058677, Applicant: ReShape Medical et al., dated: Aug. 21, 2008, 12 pages.
International Search Report; International Application No. PCT/US2008/068058, Applicant: ReShape Medical, Inc. et al, dated: Nov. 19, 2008, 11 pages.
International Search Report; International Application No. PCT/US2010/029865, Applicant: ReShape Medical, Inc., dated: Jan. 5, 2011, 9 pages.
International Search Report; International Application No. PCT/US2011/024077; Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 12 pages.
International Search Report; International Application No. PCT/US2011/024082, Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 10 pages.
International Search Report; International Application No. PCT/US1155373, Applicant: Reshape Medical, Inc., dated: Jan. 20, 2012, 7 pages.
“Living with the BIB: BioEnterics Intragastric Balloon Program: Patient Information”; INAMED Health: Bioenteris Corporation, ECO-SBA-10434; dated Apr. 20, 2004 and May 14, 2005, located online at: www.sydneyobesity.com.au/pdf/M946-01.pdf; 10 pages.
Non-Final Office Action; U.S. Appl. No. 11/694,536; dated: Oct. 26, 2011, 13 pages.
Non-Final Office Action; U.S. Appl. No. 12/723,545; dated Feb. 29, 2012, 10 pages.
Non-Final Office Action; U.S. Appl. No. 12/625,473; dated Oct. 24, 2011, 18 pages.
Non-Final Office Action; U.S. Appl. No. 12/625,473; dated Jul. 12, 2012; 10 pages.
“ReShape Inflatable Gastric Balloon Going on Trial as Weight Loss Option,” MedGadget: Internet Journal of Emerging Medical Technologies. Feb. 4, 2010, 5 pages.
Extended European Search Report; Application EP11740536.5, Applicant: ReShape Medical, Inc. mailed Jul. 3, 2014, 8 pages.
Extended European Search Report; Application EP11831683.5, Applicant: Reshape Medical, Inc., mailed Jul. 3, 2014, 8 pages.
Final Office Action; U.S. Appl. No. 13/556,032, mailed on Jan. 28, 2014, 8 pages.
Non-Final Office Action; U.S. Appl. No. 13/386,650; mailed on Jun. 3, 2014, 15 pages.
Notice of Allowance; U.S. Appl. No. 12/753,803, dated May 13, 2014, 18 pages.
Ostrovsky, ReShape Inflatable Gastric Balloon going on Trial as Weight Loss Option; http://www.medgadget.com/2010/02/reshape—inflatable—gastric—balloon—system—going—on—trial—as—weight—loss—option.html Feb. 4, 2010, retrieved on Feb. 10-13.
Final Office Action; U.S. Appl. No. 13/858,767, Mailing Date May 22, 2103, 12 pages.
Extended European Search Report; Application No. 08732989.2, Applicant: Reshape Medical, Inc., mailed Oct. 16, 2014, 7 pages.
European Examination Report; Application No. EP108002918.2, Applicant: Reshape Medical Inc., mailed Dec. 17, 2014, 5 pages.
European Examination Report; Application No. EP10802994.3, Applicant: Reshape Medical Inc., mailed Dec. 18, 2014, 4 pages.
Japanese Office Action; Application No. 2013-43712, mailed Jan. 8, 2015, 8 pages.
Canadian Office Action; Application No. 2,638,988, mailed Dec. 22, 2014, 3 pages.
Japanese Office Action; Application No. 2014-52972; mailed Feb. 25, 2015, 7 pages.
Canadian Office Action; Application No. 2,691,530, mailed Dec. 18, 2014, 4 pages.
Canadian Office Action; Application No. 2,638,163, mailed Mar. 10, 2015, 4 pages.
European Supplementary Search Report; Application No. 08771842.5, Apr. 4, 2015, 3 pages.
Non-Final Office Action; U.S. Appl. No. 11/263,302; dated: Oct. 9, 2012, 6 pages.
Non-Final Office Action; U.S. Appl. No. 12/753,751; dated Oct. 5, 2012, 8 pages.
Non-Final Office Action; U.S. Appl. No. 13/074,956; dated Oct. 1, 2012, 8pages.
Wahlen Ch et al. “The BioEnterics Intragastric Balloon: How to use it” Obesity Surgery 2001; 11:524-527.
Related Publications (1)
Number Date Country
20130060274 A1 Mar 2013 US
Provisional Applications (1)
Number Date Country
61302465 Feb 2010 US